Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
Linden
Hannah M
HM
Division of Medical Oncology, School of Medicine, University of Washington Medical Center, Seattle, WA, USA. hmlinden@u.washington.edu
Krohn
Kenneth A
KA
Livingston
Robert B
RB
Mankoff
David A
DA
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000188:drug therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D019788:Fluorodeoxyglucose F18; D000077156:Gefitinib; D005947:Glucose / Q000493:pharmacokinetics; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy; D011799:Quinazolines / Q000627:therapeutic use*; D011877:Radionuclide Imaging
D000970:Antineoplastic Agents; D011799:Quinazolines; D019788:Fluorodeoxyglucose F18; D066246:ErbB Receptors; D005947:Glucose; D000077156:Gefitinib